Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
Authors:
- Jérémie DecalfJDJérémie Decalf
- Mina AhloulayMAMina Ahloulay
- Cyril LababidiCLCyril Lababidi
- Hala MansourHMHala Mansour
- Anaïs Vallet-PichardAVAnaïs Vallet-Pichard
- Vincent MalletVMVincent Mallet
- Estelle MottezEMEstelle Mottez
- James MapesJMJames Mapes
- Arnaud FontanetAFArnaud Fontanet
- Stanislas PolSPStanislas Pol
- Matthew L. AlbertMAMatthew L. Albert
Open Access
- 4 January 2011
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 121 (1) , 308-317
Abstract
Chronic infection with hepatitis C virus (HCV) is a major public health problem, with nearly 170 million infected individuals worldwide. Current treatment for chronic infection is a combination of pegylated IFN-α2 and ribavirin (RBV); however, this treatment is effective in fewer than 50% of patients infected with HCV genotype 1 or 4. Recent studies identified the chemokine CXCL10 (also known as IP-10) as an important negative prognostic biomarker. Given that CXCL10 mediates chemoattraction of activated lymphocytes, it is counterintuitive that this chemokine correlates with therapeutic nonresponsiveness. Herein, we offer new insight into this paradox and provide evidence that CXCL10 in the plasma of patients chronically infected with HCV exists in an antagonist form, due to in situ amino-terminal truncation of the protein. We further demonstrated that dipeptidyl peptidase IV (DPP4; also known as CD26), possibly in combination with other proteases, mediates the generation of the antagonist form(s) of CXCL10. These data offer what we believe to be the first evidence for CXCL10 antagonism in human disease and identify a possible factor contributing to the inability of patients to clear HCV.Keywords
This publication has 45 references indexed in Scilit:
- Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis CHepatology, 2008
- Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulationBlood, 2008
- Stromal cell‐derived factors 1α and 1β, inflammatory protein‐10 and interferon‐inducible T cell chemo‐attractant are novel substrates of dipeptidyl peptidase 8FEBS Letters, 2008
- Elevated Serum Levels of Interferon‐γ–Inducible Protein–10 in Patients Coinfected with Hepatitis C Virus and HIVThe Journal of Infectious Diseases, 2007
- Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis CJournal of Gastroenterology and Hepatology, 2006
- Insulin resistance and HCV: Will new knowledge modify clinical management?Journal of Hepatology, 2006
- Adaptive immune responses in acute and chronic hepatitis C virus infectionNature, 2005
- Dipeptidyl peptidase IV and related enzymes in cell biology and liver disordersClinical Science, 2005
- HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus InfectionScience, 2004
- Biochemical characterization of a gamma interferon-inducible cytokine (IP-10).Journal of Experimental Medicine, 1987